Pseudotumor cerebri

Summary

Pseudotumor cerebri (MONDO:0009468) is a disease with 9 cohort genes (15 GWAS associations across 1 studies) and 42 clinical trials. Top therapeutic interventions include acetazolamide, semaglutide, and tirzepatide.

At a glance

• Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
• Cohort genes: 9
• GWAS associations: 15
• Phenotypes (HPO): 21
• Clinical trials: 42

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	1-5 / 10 000	14	Europe	Validated

Signs & symptoms

Clinical features (HPO)

21 HPO clinical features (Orphanet curated; top 21 by frequency):

HPO ID	Term	Frequency
HP:0002315	Headache	Very frequent (80-99%)
HP:0002516	Increased intracranial pressure	Very frequent (80-99%)
HP:0001085	Papilledema	Frequent (30-79%)
HP:0001513	Obesity	Frequent (30-79%)
HP:0012393	Allergy	Frequent (30-79%)
HP:0000572	Visual loss	Occasional (5-29%)
HP:0000613	Photophobia	Occasional (5-29%)
HP:0000622	Blurred vision	Occasional (5-29%)
HP:0000651	Diplopia	Occasional (5-29%)
HP:0002013	Vomiting	Occasional (5-29%)
HP:0002018	Nausea	Occasional (5-29%)
HP:0002360	Sleep abnormality	Occasional (5-29%)
HP:0010822	Scintillating scotoma	Occasional (5-29%)
HP:0100851	Abnormal emotion/affect behavior	Occasional (5-29%)
HP:0000716	Depression	Very rare (<1-4%)
HP:0001254	Lethargy	Very rare (<1-4%)
HP:0002076	Migraine	Very rare (<1-4%)
HP:0002321	Vertigo	Very rare (<1-4%)
HP:0003418	Back pain	Very rare (<1-4%)
HP:0008629	Pulsatile tinnitus	Very rare (<1-4%)
HP:0011161	Olfactory auras	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	pseudotumor cerebri
Mondo ID	MONDO:0009468
EFO	EFO:1001132
MeSH	D011559
OMIM	243200
Orphanet	238624
DOID	DOID:11459
ICD-10-CM	G93.2
ICD-11	815670637
NCIT	C85035
SNOMED CT	68267002
UMLS	C0033845
MedGen	18732
GARD	0004561
MedDRA	10037149
NORD	1294
Is cancer (heuristic)	no

Also known as: benign intracran. hypt. · benign intracranial hypertension · Idiopathic Intracranial Hypertension · idiopathic intracranial hypertension · IIH · pseudotumor cerebri

Data availability: 15 GWAS associations (1 study).

Disease family

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › arterial disorder › hypertensive disorder › intracranial hypertension › pseudotumor cerebri

Related subtypes (1): hypertensive encephalopathy

Genetics & variants

GWAS landscape

15 GWAS associations across 1 studies. Top hits map to 13 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs9578751	1e-07	PARP4, TPTE2P6	?
rs79642714	2e-07	FAM8A1	?
rs55652507	3e-07	RPL6P32 - RNA5SP199	?
rs2234671	5e-07	CXCR1	?
rs200288366	6e-07	TAS2R43, TAS2R14, PRH1, PRR4	?
rs1007175	1e-06	LINC00359	?
rs4899973	1e-06	FOXN3	?
rs12945036	1e-06	RPH3AL	?
rs11883667	2e-06	NCK2 - ECRG4	?
rs79060400	2e-06	OR9G1	?
rs78550087	2e-06	METTL25 - TMTC2	?
rs4778107	4e-06	RGMA - SEPHS1P2	?
rs35342385	5e-06	LINC02713 - CNTN5	?
rs185197019	6e-06	RNA5SP271 - KCNB2	?
rs12134151	9e-06	LINC02607	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST005688	Kuehn MH	2018	63	0	Genetic Survey of Adult-Onset Idiopathic Intracranial Hypertension.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	4
Tier 2: splice/UTR	0
Tier 3: regulatory	1
Tier 4: intronic/intergenic	10

MAF distribution

Bucket	Variants
common (>=0.05)	14
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	1

Functional consequences

Consequence	Count
intron_variant	7
missense_variant	4
intergenic_variant	2
synonymous_variant	1
regulatory_region_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs9578751	13	24500352	C>T	0.05	missense_variant	PARP4, TPTE2P6	1e-07	Tier 1: coding
rs79642714	6	17605974	G>A,T	0.05	missense_variant	FAM8A1	2e-07	Tier 1: coding
rs55652507	5	155502654	A>C	0.05	intron_variant	RPL6P32 - RNA5SP199	3e-07	Tier 4: intronic/intergenic
rs2234671	2	218164385	C>G,T	0.05	missense_variant	CXCR1	5e-07	Tier 1: coding
rs200288366	12	11092003			missense_variant	TAS2R43, TAS2R14, PRH1, PRR4	6e-07	Tier 1: coding
rs1007175	13	96960285	C>T	0.05	intron_variant	LINC00359	1e-06	Tier 4: intronic/intergenic
rs4899973	14	89272011	T>C	0.05	intron_variant	FOXN3	1e-06	Tier 4: intronic/intergenic
rs12945036	17	230930	C>A,G	0.05	intron_variant	RPH3AL	1e-06	Tier 4: intronic/intergenic
rs11883667	2	105933971	T>A,C,G	0.05	intron_variant	NCK2 - ECRG4	2e-06	Tier 4: intronic/intergenic
rs79060400	11	56701218	C>T	0.05	synonymous_variant	OR9G1	2e-06	Tier 4: intronic/intergenic
rs78550087	12	82669637	A>G	0.05	intergenic_variant	METTL25 - TMTC2	2e-06	Tier 4: intronic/intergenic
rs4778107	15	93130510	C>G,T	0.05	intron_variant	RGMA - SEPHS1P2	4e-06	Tier 4: intronic/intergenic
rs35342385	11	98135040	C>A,G,T	0.05	intergenic_variant	LINC02713 - CNTN5	5e-06	Tier 4: intronic/intergenic
rs185197019	8	72537054	G>A,C,T	0.05	regulatory_region_variant	RNA5SP271 - KCNB2	6e-06	Tier 3: regulatory
rs12134151	1	95736887	G>C	0.05	intron_variant	LINC02607	9e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Cohort genes → proteins

9 cohort genes, 8 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	9

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
RPH3AL	HGNC:10296	ENSG00000181031	Q9UNE2	Rab effector Noc2	gwas
OR9G1	HGNC:15319	ENSG00000174914	Q8NH87	Olfactory receptor 9G1	gwas
FAM8A1	HGNC:16372	ENSG00000137414	Q9UBU6	Protein FAM8A1	gwas
TAS2R43	HGNC:18875	ENSG00000255374	P59537	Taste receptor type 2 member 43	gwas
FOXN3	HGNC:1928	ENSG00000053254	O00409	Forkhead box protein N3	gwas
PARP4	HGNC:271	ENSG00000102699	Q9UKK3	Protein mono-ADP-ribosyltransferase PARP4	gwas
OR9G9	HGNC:31940	ENSG00000262191	P0C7N8	Olfactory receptor 9G9	gwas
LINC00359	HGNC:42679	ENSG00000293326		long intergenic non-protein coding RNA 359	gwas
CXCR1	HGNC:6026	ENSG00000163464	P25024	C-X-C chemokine receptor type 1	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
RPH3AL	Rab effector Noc2	Rab GTPase effector involved in the late steps of regulated exocytosis, both in endocrine and exocrine cells.
OR9G1	Olfactory receptor 9G1	Odorant receptor.
FAM8A1	Protein FAM8A1	Plays a role in the assembly of the HRD1 complex, a complex involved in the ubiquitin-proteasome-dependent process of ER-associated degradation (ERAD).
TAS2R43	Taste receptor type 2 member 43	Gustducin-coupled receptor immplicated in the perception of bitter compounds in the oral cavity and the gastrointestinal tract.
FOXN3	Forkhead box protein N3	Acts as a transcriptional repressor.
PARP4	Protein mono-ADP-ribosyltransferase PARP4	Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins.
OR9G9	Olfactory receptor 9G9	Odorant receptor.
CXCR1	C-X-C chemokine receptor type 1	Receptor to interleukin-8, which is a powerful neutrophils chemotactic factor.

Protein-family classification

Druggable: 4 · Difficult: 2 · Unknown: 3 · Druggable fraction: 0.44

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
GPCR	3	8.0×	0.020
Transcription factor	2	1.8×	0.598
Enzyme (other)	1	1.3×	0.724
Other/Unknown	3	0.6×	0.955

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
RPH3AL	Transcription factor	no		Rab_BD, Znf_FYVE_PHD, Znf_RING/FYVE/PHD
OR9G1	GPCR	yes		GPCR_Rhodpsn, Olfact_rcpt, GPCR_Rhodpsn_7TM
FAM8A1	Other/Unknown	no		RDD, FAM8A1
TAS2R43	Other/Unknown	no		TAS2R
FOXN3	Transcription factor	no		Fork_head_dom, TF_fork_head_CS_1, TF_fork_head_CS_2
PARP4	Enzyme (other)	yes	2.4.2.30	BRCT_dom, VWF_A, Poly(ADP-ribose)pol_reg_dom
OR9G9	GPCR	yes		GPCR_Rhodpsn, Olfact_rcpt, GPCR_Rhodpsn_7TM
LINC00359	Other/Unknown	no
CXCR1	GPCR	yes		Chemokine_CXCR_1/2, GPCR_Rhodpsn, Chemokine_CXCR1

Expression context

Cohort genes with no expression data: 2.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	1
moderate (6-20)	0
broad (>20)	6
unknown	2

Top tissues across cohort

Tissue	Cohort genes
male germ line stem cell (sensu Vertebrata) in testis	2
adenohypophysis	1
body of pancreas	1
pancreas	1
colonic epithelium	1
sural nerve	1
Brodmann (1909) area 23	1
choroid plexus epithelium	1
middle temporal gyrus	1
adrenal tissue	1
hindlimb stylopod muscle	1
nipple	1
paraflocculus	1
tendon of biceps brachii	1
duodenum	1
monocyte	1
rectum	1
blood	1
granulocyte	1
type B pancreatic cell	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
RPH3AL	160	broad	marker	body of pancreas, adenohypophysis, pancreas
OR9G1	1		yes	male germ line stem cell (sensu Vertebrata) in testis, sural nerve, colonic epithelium
FAM8A1	298	ubiquitous	marker	Brodmann (1909) area 23, middle temporal gyrus, choroid plexus epithelium
TAS2R43	95		yes	male germ line stem cell (sensu Vertebrata) in testis, adrenal tissue, hindlimb stylopod muscle
FOXN3	300	ubiquitous	marker	paraflocculus, tendon of biceps brachii, nipple
PARP4	134	ubiquitous	marker	rectum, duodenum, monocyte
OR9G9
LINC00359
CXCR1	148	broad	marker	blood, granulocyte, type B pancreatic cell

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
CXCR1	2,224
FOXN3	1,291
PARP4	1,209
FAM8A1	937
RPH3AL	801
TAS2R43	372
OR9G1	253
OR9G9	0
LINC00359	0

Structural data

PDB: 4 · AlphaFold-only: 4 · No structure: 1

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
PARP4	Q9UKK3	12
CXCR1	P25024	5
TAS2R43	P59537	2
FOXN3	O00409	2

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
OR9G9	P0C7N8	88.33
OR9G1	Q8NH87	85.61
RPH3AL	Q9UNE2	68.57
FAM8A1	Q9UBU6	59.45

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 16. Enrichment computed across 9 evidence-associated genes (5 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Maturation of nucleoprotein	1	207.6×	0.035	PARP4
Maturation of nucleoprotein	1	152.3×	0.035	PARP4
G alpha (i) signalling events	2	15.6×	0.035	TAS2R43, CXCR1
Nicotinate metabolism	1	78.8×	0.036	PARP4
Sensory perception of taste	1	67.2×	0.036	TAS2R43
Class C/3 (Metabotropic glutamate/pheromone receptors)	1	58.6×	0.036	TAS2R43
Sensory perception of sweet, bitter, and umami (glutamate) taste	1	55.7×	0.036	TAS2R43
Expression and translocation of olfactory receptors	2	11.2×	0.036	OR9G1, OR9G9
Chemokine receptors bind chemokines	1	37.4×	0.047	CXCR1
Olfactory Signaling Pathway	1	28.9×	0.055	OR9G1
Sensory Perception	1	19.0×	0.075	TAS2R43
GPCR ligand binding	1	12.8×	0.101	TAS2R43
GPCR downstream signalling	1	8.7×	0.135	TAS2R43
Signaling by GPCR	1	8.0×	0.136	TAS2R43
Neutrophil degranulation	1	4.6×	0.212	CXCR1
Signal Transduction	1	2.0×	0.404	TAS2R43

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 6 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
G protein-coupled receptor signaling pathway	3	18.1×	0.010	RPH3AL, TAS2R43, CXCR1
craniofacial suture morphogenesis	1	280.9×	0.026	FOXN3
positive regulation of calcium ion-dependent exocytosis	1	216.1×	0.026	RPH3AL
calcium-dependent activation of synaptic vesicle fusion	1	216.1×	0.026	RPH3AL
negative regulation of G protein-coupled receptor signaling pathway	1	200.6×	0.026	RPH3AL
dendritic cell chemotaxis	1	165.2×	0.026	CXCR1
detection of chemical stimulus involved in sensory perception of bitter taste	1	80.2×	0.044	TAS2R43
mitotic G2 DNA damage checkpoint signaling	1	73.9×	0.044	FOXN3
receptor internalization	1	54.0×	0.053	CXCR1
neutrophil chemotaxis	1	47.6×	0.053	CXCR1
positive regulation of insulin secretion	1	42.6×	0.053	RPH3AL
protein modification process	1	40.7×	0.053	PARP4
calcium-mediated signaling	1	30.5×	0.061	CXCR1
ERAD pathway	1	30.2×	0.061	FAM8A1
exocytosis	1	25.3×	0.067	RPH3AL
glucose homeostasis	1	21.8×	0.073	RPH3AL
positive regulation of cytosolic calcium ion concentration	1	19.5×	0.077	CXCR1
response to xenobiotic stimulus	1	11.5×	0.112	PARP4
intracellular protein transport	1	10.8×	0.112	RPH3AL
cell surface receptor signaling pathway	1	10.7×	0.112	CXCR1
DNA repair	1	10.6×	0.112	PARP4
DNA damage response	1	8.9×	0.127	PARP4
immune response	1	7.8×	0.137	CXCR1
inflammatory response	1	6.3×	0.161	PARP4
regulation of DNA-templated transcription	1	5.3×	0.176	FOXN3
negative regulation of DNA-templated transcription	1	5.3×	0.176	FOXN3

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

2 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Acetazolamide	Phase 3
Semaglutide	Phase 3

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 6

Druggability breadth: 3 of 9 evidence-associated genes (33%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TAS2R43	ISOPROTERENOL
PARP4	NIRAPARIB
CXCR1	DEXIBUPROFEN

Top cohort targets by molecule count

Symbol	Molecules	Max phase
CXCR1	9	4
PARP4	6	4
TAS2R43	1	4
RPH3AL	0	0
OR9G1	0	0
FAM8A1	0	0
FOXN3	0	0
OR9G9	0	0
LINC00359	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
ISOPROTERENOL	4	TAS2R43
NIRAPARIB	4	PARP4
RUCAPARIB	4	PARP4
TALAZOPARIB	4	PARP4
OLAPARIB	4	PARP4
DEXIBUPROFEN	4	CXCR1
DEXKETOPROFEN	4	CXCR1
CLOTRIMAZOLE	4	CXCR1
DICLOFENAC	4	CXCR1
ITRACONAZOLE	4	CXCR1
VELIPARIB	3	PARP4
REPARIXIN	3	CXCR1
QUERCETIN	3	CXCR1
NAVARIXIN ANHYDROUS	2	CXCR1
ATAMPARIB	1	PARP4
(R)-IBUPROPHEN	1	CXCR1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
CXCR1	120	Binding:85, Functional:35
PARP4	22	Binding:22
TAS2R43	10	Functional:10

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
PARP4	2.4.2.30	NAD+ ADP-ribosyltransferase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CXCR1	120

Pharmacogenomics

Cohort genes with a PharmGKB record: 8; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

16 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
ISOPROTERENOL	4	TAS2R43
NIRAPARIB	4	PARP4
RUCAPARIB	4	PARP4
TALAZOPARIB	4	PARP4
OLAPARIB	4	PARP4
DEXIBUPROFEN	4	CXCR1
DEXKETOPROFEN	4	CXCR1
CLOTRIMAZOLE	4	CXCR1
DICLOFENAC	4	CXCR1
ITRACONAZOLE	4	CXCR1
VELIPARIB	3	PARP4
REPARIXIN	3	CXCR1
QUERCETIN	3	CXCR1
NAVARIXIN ANHYDROUS	2	CXCR1
ATAMPARIB	1	PARP4
(R)-IBUPROPHEN	1	CXCR1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	TAS2R43, PARP4, CXCR1
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	2	OR9G1, OR9G9
E	Difficult family or no structure, no drug	4	RPH3AL, FAM8A1, FOXN3, LINC00359

Undrugged target profiles

6 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
RPH3AL	0	—
OR9G1	0	—
FAM8A1	0	—
FOXN3	0	—
OR9G9	0	—
LINC00359	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 42.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	33
PHASE3	3
PHASE4	2
PHASE2/PHASE3	1
PHASE2	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07191873	PHASE4	NOT_YET_RECRUITING	Tirzepatide in Idiopathic Intracranial Hypertension Trial
NCT06027567	PHASE4	COMPLETED	The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure
NCT01003639	PHASE2/PHASE3	COMPLETED	Idiopathic Intracranial Hypertension Treatment Trial
NCT03501966	PHASE3	TERMINATED	Surgical Idiopathic Intracranial Hypertension Treatment Trial
NCT05347147	PHASE3	TERMINATED	A Trial to Determine the Efficacy and Safety of Presendin in IIH
NCT06361823	PHASE3	UNKNOWN	Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment
NCT02017444	PHASE2	COMPLETED	Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.
NCT01407809	PHASE1	COMPLETED	Venous Sinus Stenting for Idiopathic Intracranial Hypertension Refractory to Medical Therapy
NCT03963336	EARLY_PHASE1	COMPLETED	Quantitative D-dimer Level and Anticoagulant Therapy in Idiopathic Intracranial Hypertension
NCT02896452	Not specified	ACTIVE_NOT_RECRUITING	Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome
NCT03096743	Not specified	ACTIVE_NOT_RECRUITING	Evaluating Raised Intracranial Pressure Using MR Elastography
NCT03304314	Not specified	RECRUITING	Multifocal Chromatic Pupilloperimetry in Patients With Pseudotumor Cerebri and Healthy Subjects.
NCT03556085	Not specified	ACTIVE_NOT_RECRUITING	Venous Sinus Stenting With the River Stent in IIH
NCT04032379	Not specified	RECRUITING	Diagnostic and Prognostic Biomarkers of Idiopathic Intracranial Hypertension
NCT05050864	Not specified	RECRUITING	Stenting Versus Neurosurgical Treatment of Idiopathic Intracranial Hypertension.
NCT06059703	Not specified	RECRUITING	Biomarkers in the Etiology of Idiopathic Intracranial Hypertension
NCT06436820	Not specified	NOT_YET_RECRUITING	ICP & Outflow Study
NCT06545981	Not specified	RECRUITING	Ocular Perfusion in Patients With Idiopathic Intracranial Hypertension
NCT06581185	Not specified	ENROLLING_BY_INVITATION	Pseudotumor Cerebri Headache Ten Years Outcome
NCT06692790	Not specified	RECRUITING	VEHICLE Registry: Venous Stenting for IIH in the MENA Region
NCT06833424	Not specified	NOT_YET_RECRUITING	Dural Venous Sinus Stent in Idiopathic Intracranial Hypertension
NCT06855342	Not specified	RECRUITING	Prospective Ocular Imaging for Intracranial Pressure Evaluation
NCT06856850	Not specified	RECRUITING	Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches
NCT06913712	Not specified	RECRUITING	BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment
NCT06919744	Not specified	RECRUITING	Intracranial Venous Stenting Evaluation in Patients With Idiopathic Intracranial Hypertension in the Early Phase
NCT06945848	Not specified	RECRUITING	Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide
NCT06950099	Not specified	RECRUITING	Advanced Neuroimaging in Idiopathic Intracranial Hypertension
NCT07561268	Not specified	NOT_YET_RECRUITING	Stenting Of Symptomatic Cerebral siNus stenosIs With the laserCut Self-expanding SILANCE Stent
NCT00071903	Not specified	COMPLETED	The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study
NCT01863381	Not specified	TERMINATED	Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement
NCT02124486	Not specified	UNKNOWN	An RCT of Bariatric Surgery vs a Community Weight Loss Programme for the Sustained Treatment of IIH
NCT02143258	Not specified	UNKNOWN	Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension
NCT02394067	Not specified	COMPLETED	Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension
NCT02513914	Not specified	SUSPENDED	Operative Procedures Vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial
NCT02541994	Not specified	TERMINATED	Axial Length and Central Corneal Thickness in Benign Intracranial Hypertension
NCT03867461	Not specified	COMPLETED	The Effects of MAP and EtCO2 on Venous Sinus Pressures
NCT04309383	Not specified	COMPLETED	ShuntCheck Performance Characteristics in Asymptomatic Pseudotumor Cerebri Patients
NCT04314128	Not specified	COMPLETED	Assessment of ICP in Idiopathic Intracranial Hypertension Using Transocular Ultrasound and Transcranial Doppler
NCT04603118	Not specified	COMPLETED	Optic Nerve Sheath Diameters in Idiopathic Intracranial Hypertension Patients
NCT04796935	Not specified	COMPLETED	A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ACETAZOLAMIDE	4	2
SEMAGLUTIDE	4	2
TIRZEPATIDE	4	1
AZD-4017	2	1
CHEMBL4556788	0	1
CHEMBL4752331	0	1
CHEMBL6147864	0	1